University of Hertfordshire

Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology.

Research output: Chapter in Book/Report/Conference proceedingChapter

View graph of relations
Original languageEnglish
Title of host publicationProtein Deimination in Human Health and Disease
EditorsAnthony Nicholas, Sanjoy Bhattacharya, Paul Thompson
PublisherSpringer, Cham
Pages413-425
Number of pages12
Edition2
ISBN (Electronic)978-3-319-58244-3
ISBN (Print)978-3-319-58243-6
DOIs
Publication statusPublished - 2017

Abstract

Cellular microvesicle (MV) release, which occurs in most eukaryotic cells, is also involved in cancer progression and has recently been associated with peptidylarginine deiminase (PAD)-driven protein deimination. Evidence points to the involvement of deiminated cytoskeletal proteins and changes in histone deimination in the mechanism of MV biogenesis. Elevated PAD expression observed in cancers may contribute to increased MV shedding from cancer cells and contribute to cancer progression. The use of pan-PAD inhibitor Cl-Amidine (Cl-Am) showed that, following the pharmacological inhibition of PAD-mediated deimination, cellular MV release was significantly reduced, rendering prostate cancer cells significantly more susceptible to chemotherapeutic drugs. Combined Cl-Am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX. Refined PAD inhibitors that selectively manipulate MV biogenesis may form part of novel combination therapies in cancer treatment.

Notes

Lange, Sigrun, et al, 'Treatment of prostrate cancer using deimination antagonists and microvesicle technology', in Anthony Nicholas, Sanjoy Bhattacharya, and Paul Thompson, eds., Protein Deimination in Human Health and Disease, 2nd. Edition, (Switzerland: Springer, 2017), ISBN: 978-3-319-58243-6, eBOOK ISBN: 978-3-319-58244-3, doi: 10.1007/978-3-319-58244-3.

ID: 13070676